HK Stock Market Move | Today, R sea Medical (02225) rose more than 17% to reach a new high, with revenue doubling in the first half of the year. The 4K3D fluorescence endoscope has achieved industry leadership.

In the afternoon, Jinhai Medical (02225) rose by more than 17%, hitting a high of 5.99 Hong Kong dollars, setting a new historical record. As of the time of publication, the price had increased by 17.45% to 5.99 Hong Kong dollars, with a trading volume of 4.4754 million Hong Kong dollars. In terms of news, JINHAI MED TECH previously released its interim results, with the group achieving a profit of 25.937 million Singapore dollars, an increase of 116.45% year-on-year. The announcement stated that revenue from minimally invasive surgical solutions, medical products, and related service fees increased from 400,000 Singapore dollars in the first half of 2023 to 12.3 million Singapore dollars in the first half of 2024, mainly due to the group's launch of new products in China and actively developing distribution channels, leading to growth in the minimally invasive surgical solutions business. In the analysis "Technological Breakthroughs and Market Leadership: Jinhai Medical's Rise in the High-End Endoscope Field (02225)", it is pointed out that in terms of global medical device growth, endoscopes are still a high-prosperity track, and domestically, due to a late start, the country is currently in a rapid development phase. With the continuous conversion of the R&D pipeline and the deepening of the commercialization process, Jinhai Medical is leading the way in the domestication of high-end medical equipment, especially in the rapidly growing field of endoscopes, relying on strong technology, Jinhai Medical's 4K3D Fluorescent Endoscope has already achieved industry leadership, demonstrating strong growth momentum and strong market competitiveness.